Column 1 Column 2 Column 3 Column 4 Column 5 Column 6 0 AHZ Allied confirms superior platform for stem cell growth
Column 1 0 AHZ $0.145$0.005 (3.6%)
Column 1 Column 2 0 06 Feb 2013 09:25:00
Column 1 Column 2 0 15 Views 0 comments
[/table]
Column 1 0 Sydney - Wednesday - Feb 6: (RWE Australian Business News) - A joint study with CSIRO has confirmed Allied Healthcare Group Ltd's (AHZ ) CardioCel tissue patches offer superiority for stem cell survival and growth compared with the gold-standard tissues presently in surgical use.The study compared the performance of CardioCel engineered tissue against glutaraldehyde-prepared tissue (the control), which is widely used in cardiac repair surgery, and assessed their ability to maintain a viable population of mesenchymal stems cells (MSCs)."These data further supports our recent announcement on tissue regeneration that CardioCel implants offer in reconstructing heart valves and broadens the potential of ADAPT prepared tissue to be used as scaffolds to seed and deliver stem cells for soft tissue repair," managing director Mr Lee Rodne said."This is exciting as it expands the potential of our ADAPT tissue to be used as a truly regenerative treatment for a number of diseases and conditions."The first product, CardioCel, will be launched into the global market within the next 12 months," Mr Rodne said.
Cardiocel for stem cell article, page-12
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.00 |
Change
0.000(0.00%) |
Mkt cap ! $346.0M | |||
| Open | High | Low | Value | Volume |
| $18.00 | $18.10 | $17.70 | $58.64K | 3.27K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 109 | $18.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.10 | 700 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |